(NYSE:ABBV) The brokerage firm has issued a Overweight rating on the shares.
Advertisement
Out of the 13 analysts polled by TipRanks, 9 rate AbbVie stock a Buy, 3 rate the stock a Hold and 1 recommends to Sell. Their analysts now have a $225.89 price target on that stock. The trading began at $69.99 and reached the intraday high at $70.125. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Hurwich Thomas A., Officer (VP, Controller) of Abbvie Inc., unloaded 6,200 shares at an average price of $66 on May 19, 2015. The company relies on the drug for the majority of its revenue.
Evercore ISI analyst Mark Schoenebaum weighed in today with his views on AbbVie Inc (NYSE:ABBV), as the company is scheduled to report its second-quarter earnings results on Friday, July 24, before the market opens and host a conference call at 9 am ET.
A number of analysts have recently weighed in on ABBV shares. Separately, analysts at Piper Jaffray initiated coverage on shares of AbbVie in a research note on Wednesday, June 17th. During the same quarter in the previous year, the company posted $0.82 earnings per share. On July 20, 2015 The shares registered one year high of $71.11 and one year low was seen on August 6, 2014 at $51.37. The stock has a 50-day moving average of $68.35 and a 200-day moving average of $63.46. The company has a market cap of $112.74B and a P/E ratio of 62.71.
The sell-side is overwhelmingly bullish on AbbVie stock. The share price has recorded 0.71% on a weekly basis. The total amount of the transaction was worth $409,200, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing. Their analysts now have a $57.77 price target on that stock.
AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone.
Advertisement
Meanwhile, the Pharmacyclics acquisition has diversified AbbVie’s product portfolio with the addition of Imbruvica.
